Quantbot Technologies LP Has $1.86 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Quantbot Technologies LP cut its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 26.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,450 shares of the company’s stock after selling 29,868 shares during the quarter. Quantbot Technologies LP’s holdings in Cellebrite DI were worth $1,860,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP bought a new position in Cellebrite DI during the third quarter worth $27,000. Advisors Asset Management Inc. boosted its stake in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after acquiring an additional 1,742 shares in the last quarter. R Squared Ltd bought a new position in Cellebrite DI during the fourth quarter worth $100,000. Polen Capital Management LLC bought a new position in Cellebrite DI during the fourth quarter worth $222,000. Finally, Victory Capital Management Inc. bought a new position in Cellebrite DI during the fourth quarter worth $234,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Up 1.0 %

Cellebrite DI stock opened at $19.23 on Monday. The firm’s fifty day moving average price is $21.12 and its two-hundred day moving average price is $19.80. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30. The firm has a market capitalization of $4.61 billion, a price-to-earnings ratio of -13.83, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on CLBT. Lake Street Capital increased their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.